<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="ddr21709-tbl-0004" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 4</label>
 <caption>
  <p>Therapeutic agents with anti‐inflammatory and immunomodulatory actions</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <col align="left" span="1"/>
  <thead valign="bottom">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="bottom" rowspan="1" colspan="1">Target</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Specific effect/target molecule</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Intervention(s)</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Status of SARS‐CoV‐2 trial</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">Sponsor/collaborators</th>
    <th align="left" valign="bottom" rowspan="1" colspan="1">NCT number</th>
   </tr>
  </thead>
  <tbody valign="top">
   <tr>
    <td rowspan="4" align="left" valign="top" colspan="1">Immune system</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Immunomodulatory</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Mesenchymal stem cell (MSC)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1, Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Beijing 302 Hospital, Innovative Precision Medicine Group (IPM), Hangzhou, China., Wuhan Huoshenshan Hospital, Wuhan, China, Tianjin Haihe Hospital, VCANBIO CELL &amp; GENE ENGINEERING CORP., LTD, China, Shenzhen Third People's Hospital, Fifth Affiliated Hospital, Sun Yat‐Sen University</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>NCT04252118, NCT04288102</p>
     <p>NCT04299152</p>
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Immunomodulatory</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NestCellÂ®</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Azidus Brasil, Cellavita Pesquisa CientÃfica Ltda, Hospital Vera Cruz</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04315987</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Immunomodulatory</td>
    <td align="left" valign="top" rowspan="1" colspan="1">UC‐MSCs</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">ZhiYong Peng, Tuohua Biological Technology Co. Ltd, Zhongnan Hospital; Wuhan Union Hospital, China, Wuhan Hamilton Biotechnology Co., Ltd, China.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04269525, NCT04273646</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Immunomodulatory</td>
    <td align="left" valign="top" rowspan="1" colspan="1">WJ‐MSCs</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Stem Cells Arabia</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04313322</td>
   </tr>
   <tr>
    <td rowspan="19" align="left" valign="top" colspan="1">Immune system</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Angiotensin II receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Losartan</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">University of Minnesota</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04312009, NCT04311177</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Cytokine</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Dexamethasone</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Dr. Negrin University Hospital, Li Ka Shing Knowledge Institute</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04325061</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Cytokine</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Methylprednisolone</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3, Phase 4</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Beijing Chao Yang Hospital; Tongji Hospital; Peking Union Medical College Hospital, Zhongda Hospital, Zhongnan Hospital, Renmin Hospital of Wuhan University; University of Trieste</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04273321, NCT04263402, NCT04244591, NCT04323592</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Cytokine</td>
    <td align="left" valign="top" rowspan="1" colspan="1">MSCs‐derived exosomes</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Ruijin Hospital, Shanghai Public Health Clinical Center, Wuhan Jinyintan Hospital, Wuhan, China, Cellular Biomedicine Group Ltd.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04276987</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Eicosanoids and nuclear factor‐kappa B (NF‐kB)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Escin</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">University of Catanzaro, Azienda Ospedaliera Pugliese Ciaccio, Azienda Ospedaliera Policlinico "Mater Domini"</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04322344</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Infected human cells</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NK cells, IL15‐NK cells, NKG2D CAR‐NK cells, ACE2 CAR‐NK cells,NKG2D‐ACE2 CAR‐NK cells</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 1, Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Chongqing Public Health Medical Center, Chongqing Sidemu Biotechnology Technology Co., Ltd., Xinxiang medical university, First Affiliated Hospital of Xinjiang Medical University</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04324996, NCT04280224</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Injured cell components</td>
    <td align="left" valign="top" rowspan="1" colspan="1">CD24Fc</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">OncoImmune, Inc.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04317040</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interferon gamma (IFNy)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Emapalumab</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Swedish Orphan Biovitrum</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04324021</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interferon receptor (IFNAR)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Recombinant human interferon Alpha‐1b</p>
     <p>†2 thymosin alpha 1</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Shanghai Jiao Tong University School of Medicine</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04320238</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interferon receptor (IFNAR)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Recombinant human interferon Î ± 1Î
     <sup>2</sup>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Early Phase 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Tongji Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04293887</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interleukin‐1 type 1 receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Anakinra</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Swedish Orphan Biovitrum</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04324021</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interleukin‐1 type 1 receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 RoActemra iv</p>
     <p>†2 RoActemra sc</p>
     <p>†3 Kevzara sc</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Marius Henriksen, Lars Erik Kristensen, Frederiksberg University Hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04322773</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interleukin‐1 type 1 receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Sarilumab</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Assistance Publique ‐ HÃ´pitaux de Paris; Regeneron Pharmaceuticals, Sanofi</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04324073, NCT04315298</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interleukin‐6 receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Tocilizumab</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2, Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">UniversitÃ Politecnica delle Marche, Azienda Ospedaliera Ospedali Riuniti Marche Nord; Hoffmann‐La Roche, National Cancer Institute, Naples; Tongji Hospital, Hubei Xinhua Hospital, Wuhan No.1 Hospital, Wuhan central hospital</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04315480, NCT04320615, NCT04317092, NCT04306705</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Interleukin‐6, TNFα</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Aviptadil</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NeuroRx, Inc., Relief Therapeutics Holding SA</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04311697</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Programmed cell death protein 1</td>
    <td align="left" valign="top" rowspan="1" colspan="1">
     <p>†1 Programmed death‐1 (PD‐1) blocking antibody +standard treatment</p>
     <p>†2 Thymosin + standard treatment</p>
    </td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Southeast University, China</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04268537</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Prostaglandins</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Naproxen</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 3</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Assistance Publique ‐ HÃ´pitaux de Paris</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04325633</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Sphingosine 1‐phosphate (S1P) receptor</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Fingolimod</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">First Affiliated Hospital of Fujian Medical University</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04280588</td>
   </tr>
   <tr>
    <td align="left" valign="top" rowspan="1" colspan="1">Toll‐like receptor (TLR)</td>
    <td align="left" valign="top" rowspan="1" colspan="1">PUL‐042 Inhalation Solution</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Phase 2</td>
    <td align="left" valign="top" rowspan="1" colspan="1">Pulmotect, Inc.</td>
    <td align="left" valign="top" rowspan="1" colspan="1">NCT04313023, NCT04312997</td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot id="ddr21709-ntgp-0004">
  <fn id="ddr21709-note-0004">
   <p>
    <italic>Note:</italic> †1, †2, and †3 are different arms of parallel intervention.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
